• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    8/25/23 1:31:20 PM ET
    $APM
    $CANO
    $IMPL
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Cano Health (NYSE:CANO) shares rose 58.7% to $0.37 during Friday's regular session. As of 13:31 EST, Cano Health's stock is trading at a volume of 98.0 million, which is 1253.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $104.2 million.
    • YS Biopharma Co (NASDAQ:YS) stock increased by 41.19% to $1.1. As of 13:31 EST, this security is trading at a volume of 38.1 million shares, making up 5860.1% of its average full-day volume over the last 100 days. The company's market cap stands at $102.3 million.
    • Aptorum Gr (NASDAQ:APM) stock increased by 34.37% to $2.37. As of 13:31 EST, this security is trading at a volume of 6.2 million shares, making up 51928.3% of its average full-day volume over the last 100 days. The company's market cap stands at $9.8 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) stock increased by 20.22% to $0.53. Trading volume for this security as of 13:31 EST is 219.1K, which is 29.9% of its average full-day volume over the last 100 days. The company's market cap stands at $12.5 million.
    • NeuroPace (NASDAQ:NPCE) stock rose 17.82% to $6.08. The market value of their outstanding shares is at $157.2 million.
    • Precigen (NASDAQ:PGEN) stock increased by 14.05% to $1.75. Trading volume for Precigen's stock is 4.1 million as of 13:31 EST. This is 254.5% of its average full-day volume over the last 100 days. The company's market cap stands at $445.8 million.

    Losers

    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares fell 43.6% to $0.02 during Friday's regular session. Trading volume for Longeveron Inc. - Subscription Right's stock is 174.8K as of 13:31 EST. This is 39.2% of its average full-day volume over the last 100 days.
    • Pieris Pharmaceuticals (NASDAQ:PIRS) shares fell 23.21% to $0.33. As of 13:31 EST, this security is trading at a volume of 7.8 million shares, making up 236.1% of its average full-day volume over the last 100 days. The company's market cap stands at $32.6 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 19.41% to $0.12. As of 13:31 EST, China SXT Pharmaceuticals's stock is trading at a volume of 3.4 million, which is 115.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares declined by 17.89% to $0.72. NeuBase Therapeutics's stock is trading at a volume of 296.8K shares as of 13:31 EST. This is 127.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 million.
    • Mallinckrodt (AMEX:MNK) stock declined by 17.78% to $0.33. The current volume of 408.6K shares is 11.3% of Mallinckrodt's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $4.3 million.
    • Minerva Surgical (NASDAQ:UTRS) shares fell 16.47% to $0.2. The current volume of 538.6K shares is 13.9% of Minerva Surgical's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $36.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $CANO
    $IMPL
    $MNK

    CompanyDatePrice TargetRatingAnalyst
    Precigen Inc.
    $PGEN
    8/15/2025Underweight → Neutral
    Analyst
    Neuropace Inc.
    $NPCE
    5/28/2025$18.00Buy
    H.C. Wainwright
    Neuropace Inc.
    $NPCE
    1/21/2025$17.00Buy
    UBS
    Precigen Inc.
    $PGEN
    3/22/2024Neutral → Underweight
    JP Morgan
    Neuropace Inc.
    $NPCE
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    Neuropace Inc.
    $NPCE
    1/30/2024$22.00Outperform
    Leerink Partners
    Neuropace Inc.
    $NPCE
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    Neuropace Inc.
    $NPCE
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $APM
    $CANO
    $IMPL
    $MNK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement. During this period, Aptorum Group Limited intends to evaluate all available options to restore comp

    3/6/26 4:30:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuroPace to Present at the Leerink Global Healthcare Conference

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused o

    3/5/26 4:30:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    SEC Filings

    View All

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/6/26 4:30:58 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Neuropace Inc.

    S-8 - NeuroPace Inc (0001528287) (Filer)

    3/3/26 5:29:33 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Neuropace Inc.

    10-K - NeuroPace Inc (0001528287) (Filer)

    3/3/26 4:54:02 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precigen upgraded by Analyst

    Analyst upgraded Precigen from Underweight to Neutral

    8/15/25 8:13:17 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on NeuroPace with a new price target

    H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

    5/28/25 9:08:28 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on NeuroPace with a new price target

    UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

    1/21/25 8:23:18 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Shah Rutul R bought $6,800 worth of shares (2,000 units at $3.40), increasing direct ownership by 0.50% to 405,959 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:07:27 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Tennant Phil bought $21,480 worth of shares (6,000 units at $3.58), increasing direct ownership by 10% to 65,031 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/30/25 4:04:51 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    3/4/26 4:43:28 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 5,023 shares, decreasing direct ownership by 5% to 96,937 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    3/4/26 4:41:36 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 101,960 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    3/2/26 4:46:29 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroPace Announces Strategic CFO Transition

    Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

    6/24/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Precigen Reports First Quarter 2025 Financial Results and Business Updates

    PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

    5/14/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

    – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

    4/16/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Financials

    Live finance-specific insights

    View All

    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

    -- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To

    3/3/26 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's in

    2/20/26 4:30:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    --Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- -- 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE)-- --IGE is expected following potential approval in the second half of 2026-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million,

    1/13/26 7:30:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $APM
    $CANO
    $IMPL
    $MNK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 6:30:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 3:36:16 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care